Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yifan, Song, Jialong, Li, Xinyi, Luo, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408844/
https://www.ncbi.nlm.nih.gov/pubmed/36012144
http://dx.doi.org/10.3390/ijms23168878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408844/
https://www.ncbi.nlm.nih.gov/pubmed/36012144
http://dx.doi.org/10.3390/ijms23168878

Ejemplares similares